CereSpir Incorporated is Pleased With Positive Interim Phase 2 Results for CHF 5074 in Patients With Mild Cognitive Impairment, Presented by Chiesi Farmaceutici SpA at the AAIC 2013 Meeting in Boston
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated announced positive interim clinical results from Chiesi Farmaceutici's Phase 2 study testing CHF 5074, a novel, first-in-class small molecule microglia modulator, in patients with mild cognitive impairment (MCI). The 90-week study, which included a 96-patient 14-week double-blind, placebo-controlled study and an ongoing 76-week open-label extension study, tested three titrated doses of CHF 5074 (200 mg, 400 mg, 600 mg dosed orally once daily) in MCI patients. Upon completion of the 14-week study,
Help employers find you! Check out all the jobs and post your resume.
NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpir™ Incorporated announced positive interim clinical results from Chiesi Farmaceutici's Phase 2 study testing CHF 5074, a novel, first-in-class small molecule microglia modulator, in patients with mild cognitive impairment (MCI). The 90-week study, which included a 96-patient 14-week double-blind, placebo-controlled study and an ongoing 76-week open-label extension study, tested three titrated doses of CHF 5074 (200 mg, 400 mg, 600 mg dosed orally once daily) in MCI patients. Upon completion of the 14-week study,
Help employers find you! Check out all the jobs and post your resume.